Benzinga | Aug 4, 2021 07:26AM EDT

Pieris Pharmaceuticals Q2 EPS $(0.25) Beats $(0.26) Estimate, Sales $3.29M Beat $2.07M Estimate

Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 177.78 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $3.29 million which beat the analyst consensus estimate of $2.07 million by 58.70 percent. This is a 70.79 percent decrease over sales of $11.25 million the same period last year.